Half life of Alprazolam in hepatic insufficient patients
Biomedica. 2001; 17 (2): 4-6
en Inglés
| IMEMR
| ID: emr-56480
ABSTRACT
Alprazolam is a triazolobenzodiazepine which is primarily metabolized by the liver. To see its half life in hepatic insufficient patients tab. Alprazolam in a dose of 0.25 mg, B.D. was given orally to 15 such patients and 5 normal subjects taken as control. Drug was given for a period of 21 days to both groups. Blood samples were drawn at day 7 and 21. There was no remarkable change in half life on day 7 and 21, among control group. Same results were seen among hepatic group on both days but half life increased to about double on day 7 and 21, when compared to control ones. Thus, it was concluded that in hepatic insufficient patients, half life increases significantly due to alteration in hepatic biotransformation mechanism
Buscar en Google
Índice:
IMEMR (Mediterraneo Oriental)
Asunto principal:
Triazolam
/
Fallo Hepático
/
Semivida
/
Hepatopatías
Límite:
Femenino
/
Humanos
/
Masculino
Idioma:
Inglés
Revista:
Biomedica
Año:
2001
Similares
MEDLINE
...
LILACS
LIS